Effect of aflibercept on proliferative vitreoretinopathy: Proteomic analysis in an experimental animal model

被引:5
|
作者
Uslubas, Isil [1 ,3 ]
Kanli, Aylin [2 ]
Kasap, Murat [2 ]
Akpinar, Gurler [2 ]
Karabas, Levent [1 ]
机构
[1] Kocaeli Univ, Dept Ophthalmol, Sch Med, Kocaeli, Turkey
[2] Kocaeli Univ, Dept Med Biol, Sch Med, Kocaeli, Turkey
[3] Golcuk Necati Celik State Hosp, TR-41650 Kocaeli, Turkey
关键词
Proliferative vitreoretinopathy; Aflibercept; Dispase; Proteomic; Animal model;
D O I
10.1016/j.exer.2020.108425
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to monitor inflammatory, proliferative and progressive effects of proliferative vitreoretinopathy (PVR) and aflibercept treatment in dispase induced PVR rat model by proteomic analysis. Material and methods: A total of 35 male Long Evans pigmented rats were divided into three groups, namely, PVR (dispase+saline), PVR+aflibercept (dispase+aflibercept) and control. The PVR group received 2 mu l of 0.03 IU/mu l dispase and 2 mu l saline, the PVR+aflibercept group received 2 mu l of 0.03 IU/mu l and 2 mu l of 40 mg/ml aflibercept at the first day of the experiment. At the end of the 6th week all retina and vitreous specimens were collected by evisceration and transferred to the proteomics laboratory for analysis. Proteomic analysis by 2D gel electrophoresis coupled with MALDI-TOF/TOF was performed. Results: In the PVR and PVR+aflibercept group 16 different proteins that were identified to be differentially regulated in comparison to the control group. In the PVR+aflibercept group, ENO1, ENO2, LDH-B, PEBP-1 and GS levels were higher than the PVR group. In addition, the association of proteins such as UCHL, PEBP1, PDHB and ENO1 with PVR has been demonstrated for the first time. Conclusion: STRING analysis elucidated the functional protein-protein interaction among the differentially regulated proteins and highlighted that those proteins mainly played roles in carbon and nucleotide metabolisms. Functional analysis of the differentially regulated proteins indicated the presence of inflammation, gliosis and retinal damage in the PVR group. Aflibercept treatment had pronounced effect on prevention of inflammation and retinal damage while causing a slight increase in gliosis. However, aflibercept treatment was not effective enough to normalize the levels of differentially regulated proteins of the PVR group. Therefore, we predict that the treatment dose of aflibercept used in this study was below of its ideal concentration and should be increased in the future studies. The differential regulation of these structural proteins in this study should shed some light to the mechanism of glial wound formation in the retina and guide future treatment modalities.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] siRNA targeting mammalian target of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy
    Zhou, Peng
    Zhao, Ming-Wei
    Li, Xiao-Xin
    Yu, Wen-Zhen
    Bian, Zong-Mei
    CURRENT EYE RESEARCH, 2007, 32 (11) : 973 - 984
  • [42] EGF Receptor Signaling Modulates YAP Activation and Promotes Experimental Proliferative Vitreoretinopathy
    Zhang, Wei
    Li, Jing
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (08)
  • [43] The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy
    Ozerdem, U
    Mach-Hofacre, B
    Cheng, LY
    Chaidhawangul, S
    Keefe, K
    McDermott, CD
    Bergeron-Lynn, G
    Appelt, K
    Freeman, WR
    CURRENT EYE RESEARCH, 2000, 20 (06) : 447 - 453
  • [44] Protein Kinase A Inhibitor H89 Attenuates Experimental Proliferative Vitreoretinopathy
    Lyu, Yali
    Xu, Wei
    Zhang, Jieping
    Li, Mengwen
    Xiang, Qingyi
    Li, Yao
    Tan, Tianhao
    Ou, Qingjian
    Zhang, Jingfa
    Tian, Haibin
    Xu, Jing-Ying
    Jin, Caixia
    Gao, Furong
    Wang, Juan
    Li, Weiye
    Rong, Ao
    Lu, Lixia
    Xu, Guo-Tong
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (02)
  • [45] Transferrin-ricin a chain toxin limits the development of experimental proliferative vitreoretinopathy
    Handa, JT
    Keithahn, MA
    Jaffe, GJ
    EXPERIMENTAL EYE RESEARCH, 1996, 62 (06) : 689 - 695
  • [46] RETINOIC ACID IN SILICONE AND SILICONE-FLUOROSILICONE COPOLYMER OILS IN A RABBIT MODEL OF PROLIFERATIVE VITREORETINOPATHY
    NAKAGAWA, M
    REFOJO, MF
    MARIN, JF
    DOI, M
    TOLENTINO, FI
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (12) : 2388 - 2395
  • [47] SUPPRESSION OF EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY BY SUSTAINED INTRAOCULAR DELIVERY OF 5-FU
    BORHANI, H
    PEYMAN, GA
    RAHIMY, MH
    THOMPSON, H
    INTERNATIONAL OPHTHALMOLOGY, 1995, 19 (01) : 43 - 49
  • [48] ACLACINOMYCIN-A IN THE TREATMENT OF EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY - EFFICACY AND TOXICITY IN THE RABBIT EYE
    STEINHORST, UH
    CHEN, EP
    HATCHELL, DL
    SAMSA, GP
    SALOUPIS, PT
    WESTENDORF, J
    MACHEMER, R
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (05) : 1753 - 1760
  • [49] SU9518 Inhibits Proliferative Vitreoretinopathy (PVR) in a Rabbit Model
    Velez, G.
    Kazlauskas, A.
    Young, M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [50] Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy
    Szczesniak, Anna-Maria
    Porter, Richard F.
    Toguri, James T.
    Borowska-Fielding, Joanna
    Gebremeskel, Simon
    Siwakoti, Anuja
    Johnston, Brent
    Lehmann, Christian
    Kelly, Melanie E. M.
    NEUROPHARMACOLOGY, 2017, 113 : 627 - 638